Literature DB >> 25433414

Implications of imaging criteria for the management and treatment of intraductal papillary mucinous neoplasms - benign versus malignant findings.

Thula Cannon Walter1, Ingo G Steffen, Lars H Stelter, Martin H Maurer, Marcus Bahra, Wladimir Faber, Fritz Klein, Hendrik Bläker, Bernd Hamm, Timm Denecke, Christian Grieser.   

Abstract

OBJECTIVES: Evaluation of computed tomography (CT) and magnetic resonance imaging (MRI) for differentiation of pancreatic intraductal papillary mucinous neoplasm (IPMN) subtypes based on objective imaging criteria.
METHODS: Fifty-eight patients with 60 histologically confirmed IPMNs were included in this retrospective study. Eighty-three imaging studies (CT,n = 42; MRI,n = 41) were analysed by three independent blinded observers (O1-O3), using established imaging criteria to assess likelihood of malignancy (-5, very likely benign; 5, very likely malignant) and histological subtype (i.e., low-grade (LGD), moderate-grade (MGD), high-grade dysplasia (HGD), early invasive carcinoma (IPMC), solid carcinoma (CA) arising from IPMN).
RESULTS: Forty-one benign (LGD IPMN,n = 20; MGD IPMN,n = 21) and 19 malignant (HGD IPMN,n = 3; IPMC,n = 6; solid CA,n = 10) IPMNs located in the main duct (n = 6), branch duct (n = 37), or both (n = 17) were evaluated. Overall accuracy of differentiation between benign and malignant IPMNs was 86/92 % (CT/MRI). Exclusion of overtly malignant cases (solid CA) resulted in overall accuracy of 83/90 % (CT/MRI). The presence of mural nodules and ductal lesion size ≥30 mm were significant indicators of malignancy (p = 0.02 and p < 0.001, respectively).
CONCLUSIONS: Invasive IPMN can be identified with high confidence and sensitivity using CT and MRI. The diagnostic problem that remains is the accurate radiological differentiation of premalignant and non-invasive subtypes. KEY POINTS: • CT and MRI can differentiate benign from malignant forms of IPMN. • Identifying (pre)malignant histological IPMN subtypes by CT and MRI is difficult. • Overall, diagnostic performance with MRI was slightly (not significantly) superior to CT.

Entities:  

Mesh:

Year:  2014        PMID: 25433414     DOI: 10.1007/s00330-014-3520-3

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  51 in total

1.  Incidental pancreatic cysts on 3D turbo spin echo magnetic resonance cholangiopancreatography: prevalence and relation with clinical and imaging features.

Authors:  Rossano Girometti; Sergio Intini; Giovanni Brondani; Giuseppe Como; Francesco Londero; Fabrizio Bresadola; Chiara Zuiani; Massimo Bazzocchi
Journal:  Abdom Imaging       Date:  2011-04

2.  Differentiating xanthogranulomatous cholecystitis from wall-thickening type of gallbladder cancer: added value of diffusion-weighted MRI.

Authors:  T W Kang; S H Kim; H J Park; S Lim; K M Jang; D Choi; S J Lee
Journal:  Clin Radiol       Date:  2013-04-25       Impact factor: 2.350

3.  Development of pancreatic cancers during long-term follow-up of side-branch intraductal papillary mucinous neoplasms.

Authors:  Y Sawai; K Yamao; V Bhatia; T Chiba; N Mizuno; A Sawaki; K Takahashi; M Tajika; Y Shimizu; Y Yatabe; A Yanagisawa
Journal:  Endoscopy       Date:  2010-11-30       Impact factor: 10.093

4.  Diffusion-weighted imaging in characterization of cystic pancreatic lesions.

Authors:  K Sandrasegaran; F M Akisik; A A Patel; M Rydberg; H M Cramer; N P Agaram; C M Schmidt
Journal:  Clin Radiol       Date:  2011-05-20       Impact factor: 2.350

5.  Extent of surgical resections for intraductal papillary mucinous neoplasms.

Authors:  Stefano Crippa; Stefano Partelli; Massimo Falconi
Journal:  World J Gastrointest Surg       Date:  2010-10-27

6.  An aggressive surgical approach is warranted in the management of cystic pancreatic neoplasms.

Authors:  Jeffrey M Hardacre; Michael F McGee; Thomas A Stellato; James A Schulak
Journal:  Am J Surg       Date:  2007-03       Impact factor: 2.565

7.  Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development.

Authors:  Jian Wu; Hanno Matthaei; Anirban Maitra; Marco Dal Molin; Laura D Wood; James R Eshleman; Michael Goggins; Marcia I Canto; Richard D Schulick; Barish H Edil; Christopher L Wolfgang; Alison P Klein; Luis A Diaz; Peter J Allen; C Max Schmidt; Kenneth W Kinzler; Nickolas Papadopoulos; Ralph H Hruban; Bert Vogelstein
Journal:  Sci Transl Med       Date:  2011-07-20       Impact factor: 17.956

8.  Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients.

Authors:  Stefano Crippa; Roberto Salvia; Andrew L Warshaw; Ismael Domínguez; Claudio Bassi; Massimo Falconi; Sarah P Thayer; Giuseppe Zamboni; Gregory Y Lauwers; Mari Mino-Kenudson; Paola Capelli; Paolo Pederzoli; Carlos Fernández-del Castillo
Journal:  Ann Surg       Date:  2008-04       Impact factor: 12.969

9.  Intraductal papillary mucinous neoplasm of the pancreas: assessment of the likelihood of invasiveness with multisection CT.

Authors:  Hiroshi Ogawa; Shigeki Itoh; Mitsuru Ikeda; Kojiro Suzuki; Shinji Naganawa
Journal:  Radiology       Date:  2008-07-15       Impact factor: 11.105

10.  Small (Sendai negative) branch-duct IPMNs: not harmless.

Authors:  Stefan Fritz; Miriam Klauss; Frank Bergmann; Thilo Hackert; Werner Hartwig; Oliver Strobel; Bogata D Bundy; Markus W Büchler; Jens Werner
Journal:  Ann Surg       Date:  2012-08       Impact factor: 12.969

View more
  7 in total

1.  Comparison between MRI with MR cholangiopancreatography and endoscopic ultrasonography for differentiating malignant from benign mucinous neoplasms of the pancreas.

Authors:  Jiyoung Hwang; Young Kon Kim; Ji Hye Min; Woo Kyung Jeong; Seong Sook Hong; Hyun-Joo Kim
Journal:  Eur Radiol       Date:  2017-08-04       Impact factor: 5.315

2.  Validation of the American Gastroenterological Association guidelines on management of intraductal papillary mucinous neoplasms: more than 5 years of follow-up.

Authors:  Koh Imbe; Naoyoshi Nagata; Yuya Hisada; Yusuke Takasaki; Katsunori Sekine; Saori Mishima; Akihito Kawazoe; Tsuyoshi Tajima; Takuro Shimbo; Mikio Yanase; Junichi Akiyama; Kazuma Fujimoto; Naomi Uemura
Journal:  Eur Radiol       Date:  2017-08-02       Impact factor: 5.315

3.  Pancreatic MRI for the surveillance of cystic neoplasms: comparison of a short with a comprehensive imaging protocol.

Authors:  Raffaella Maria Pozzi-Mucelli; Irina Rinta-Kiikka; Katharina Wünsche; Johanna Laukkarinen; Knut Jørgen Labori; Kim Ånonsen; Caroline Verbeke; Marco Del Chiaro; Nikolaos Kartalis
Journal:  Eur Radiol       Date:  2016-05-31       Impact factor: 5.315

Review 4.  Imaging modalities for characterising focal pancreatic lesions.

Authors:  Lawrence Mj Best; Vishal Rawji; Stephen P Pereira; Brian R Davidson; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-04-17

5.  Fate of small pancreatic cysts (<3 cm) after long-term follow-up: analysis of significant radiologic characteristics and proposal of follow-up strategies.

Authors:  Heera Yoen; Jung Hoon Kim; Dong Ho Lee; Su Joa Ahn; Jeong Hee Yoon; Joon Koo Han
Journal:  Eur Radiol       Date:  2016-09-21       Impact factor: 5.315

6.  Efficacy of oral contrast agents for upper gastrointestinal signal suppression in MRCP: A systematic review of the literature.

Authors:  Anne Frisch; Thula C Walter; Bernd Hamm; Timm Denecke
Journal:  Acta Radiol Open       Date:  2017-08-30

Review 7.  Predictive performance of factors associated with malignancy in intraductal papillary mucinous neoplasia of the pancreas.

Authors:  M Heckler; L Brieger; U Heger; T Pausch; C Tjaden; J Kaiser; M Tanaka; T Hackert; C W Michalski
Journal:  BJS Open       Date:  2018-02-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.